Why this chain matters

Eli Lilly and Company (LLY) has a mapped ChainSifter graph with 14 supplier links and 14 customer links. That makes it useful for investors trying to understand who benefits when LLY performs well, and who may be exposed if demand or execution weakens.

The point is not to treat every edge as equal. The useful signal is the shape of the network: named suppliers, named customers, confidence levels, and filing language that shows where business dependence may sit.

Supplier exposure

The supplier side shows the companies and entities most directly tied to LLY's operating base. Higher-confidence links deserve the first review because they are the relationships most likely to matter when margins, production, procurement, or delivery timelines change.

  • Incyte Corporation (INCY) - confidence 95%.
  • Ventyx Biosciences Inc (VTYX) - confidence 92%.
  • Aclaris Therapeutics, Inc. (ACRS) - confidence 92%.
  • BOEHRINGER-INGELHEIM (BOEHRINGER-INGELHEIM) - confidence 92%.
  • GENENTECH-INC (GENENTECH-INC) - confidence 90%.
  • OPKO Health, Inc. (OPK) - confidence 85%.
  • ProQR Therapeutics N.V. (PRQR) - confidence 85%.
  • Crinetics Pharmaceuticals, Inc. (CRNX) - confidence 85%.

Customer and demand signals

The customer side is where revenue concentration and downstream demand risk usually show up first. If a customer relationship is central to the graph, a change in that customer's spending or inventory cycle can move through the chain quickly.

  • USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS (USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS) - confidence 95%.
  • Spruce Biosciences, Inc. (SPRB) - confidence 92%.
  • AC Immune SA (ACIU) - confidence 92%.
  • Immuneering Corporation (IMRX) - confidence 92%.
  • BOEHRINGER-INGELHEIM (BOEHRINGER-INGELHEIM) - confidence 92%.
  • Foghorn Therapeutics Inc. (FHTX) - confidence 90%.
  • ALMIRALL-S-A (ALMIRALL-S-A) - confidence 90%.
  • Aclaris Therapeutics, Inc. (ACRS) - confidence 80%.

Filing evidence

ChainSifter is most useful when the map is tied back to source language. These excerpts are the evidence trail behind the graph and should be reviewed before treating a relationship as investable signal.

  • Incyte Corporation: Reciprocal relationship from INCY graph: ervice institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a disco
  • Eli Lilly and Company: USAspending awards from Department of Veterans Affairs: $281,860 across 2 awards. 36C25026N0080 AMYVID RADIOPHARMACEUTICAL 10 MCI FLORBETAPIR F-18 INJ,SOLN; 36C26226N0579 F-18 AMYVID B+4 | Qwen corrected direction: Explicit government contract awards from Depa
  • Eli Lilly and Company: Reciprocal relationship from IMRX graph: In August 2025, we announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982), which intends to support the evaluation of atebimetinib in combi
  • Eli Lilly and Company: Jardiance revenue outside the U.S. included one-time benefits of $250 million in Q1 2026 compared to $370 million in Q1 2025, associated with the company's collaboration with Boehringer Ingelheim.
  • Eli Lilly and Company: Reciprocal relationship from ACIU graph: ave achieved and our goal of a close working relationship with the regulatory agencies, in particular the FDA and the EMA, are intended to facilitate expeditious execution through the regulatory approval process. Our re

Who benefits and who is exposed

If Eli Lilly and Company outperforms, the first-order beneficiaries are the suppliers with high-confidence relationships and the customers that rely on the company's output. If LLY struggles, the exposed names are the counterparties with fewer alternate channels or relationships that appear repeatedly in the filing trail.

This is the practical use case: map the counterparties, separate confirmed relationships from weak ones, and watch for new filings that change the direction or concentration of exposure.

The most important follow-up is not simply whether a counterparty appears once. It is whether the same relationship persists across filings, appears in risk-factor language, or connects to revenue, procurement, capacity, or delivery obligations. Those are the details that turn a graph edge into investable supply chain intelligence.

How to read the signal

A compact graph can still be useful when the named counterparties are specific and the evidence is direct. Investors should read each relationship as a working hypothesis about exposure, then compare it with revenue mix, segment performance, margin pressure, and management commentary in the next filing cycle.

The strongest signals usually have three traits: a named counterparty, a clear commercial role, and repeated language over time. A one-off mention is weaker. A relationship tied to manufacturing, purchasing, licensing, distribution, or customer concentration is stronger because it can affect revenue durability, operating leverage, or execution risk.

For Eli Lilly and Company, the current graph gives analysts a starting map rather than a final conclusion. The supplier side points to operating dependencies. The customer side points to demand dependencies. The evidence trail shows which edges deserve deeper work before they are used in a trade or portfolio risk review.

What to watch

  • New or removed supplier names in future filings.
  • Customer concentration language that points to revenue dependence.
  • Confidence changes in the ChainSifter graph as new evidence is processed.